Core Viewpoint - The acquisition of 75% equity in SEA3 by Zhonghong Medical for a mere 6.97 yuan is perceived as a "bargain" deal, but it reflects the company's ongoing financial struggles and the risks associated with the acquisition [1][4]. Group 1: Acquisition Details - Zhonghong Medical's wholly-owned subsidiary, Zhonghong International, and its controlling subsidiary, Guilin Hengbao, signed an agreement to acquire 75% of SEA3 for a total of 6.97 yuan [1][3]. - SEA3, established in September 2016, specializes in the production and sale of medical gloves and has certifications for compliance with EU and US market standards [2][4]. - As of the end of last year, SEA3 had total assets of 141 million yuan and a net asset value of -1.2 million yuan, indicating financial distress [2][4]. Group 2: Financial Assessment - The assessed value of SEA3's total equity was determined to be 802,300 yuan, reflecting a significant increase of 271,240 yuan (142%) over its book value [2][3]. - The transaction price was based on this assessed value, with Zhonghong International acquiring 52.5% and Hengbao acquiring 22.5% of the equity [3]. Group 3: Strategic Intent - The primary goal of the acquisition is to secure a production base in Southeast Asia, which is crucial for adapting to changes in the international trade environment [5][6]. - Zhonghong Medical aims to leverage SEA3's existing certifications and production capabilities to enhance its market position and overall competitiveness in the medical supplies industry [5][6]. Group 4: Future Outlook - Despite SEA3's current operational challenges, Zhonghong Medical remains optimistic about the future growth of the medical glove market, anticipating increased demand driven by global health trends [5][6]. - The company plans to implement effective post-investment management and operational synergies to help SEA3 return to profitability [5][6].

以下文章来源于e公司 ，作者证券时报 曾剑 拟并购标的总资产上亿 SEA3公司成立于2016年9月，注册地位于东南亚，注册资本为6333万元。公司股东包括SEA3集团以及6名自然人。上市公司称交易对手与其不存在关 联。 e公司 . e公司，证券时报旗下专注上市公司新媒体产品，立志打造A股上市公司资讯第一平台。提供7x24小时上市公司标准化快讯，针对可能影响上市公司股价 的主题概念、行业事件及时采访二次解读，从投资者需求出发，直播上市公司有价值的活动、会议。 花几块钱就能在东南亚买下一家资产上亿的企业？此事真实发生。 中红医疗（300981）近日披露，其全资子公司中红香港、下属桂林恒保防护国际有限公司（下称"桂林恒保"）签署股份买卖协议和股东协议， 收购东 南亚SEA3公司（下称"SEA3公司"）合计75%股权。 证券时报·e公司记者注意到，SEA3公司75%股权的交易价格仅为6.97元，由中红香港、桂林恒保分别支付4.88元和2.09元。 中红医疗主要从事高品质一次性健康防护用品、医用无菌器械等产品的研发、生产与销售，属于医疗器械行业。 公司产品包括一次性健康防护手套、安 全输注产品（注射器、输液器等）、避孕 ...

Core Viewpoint - The recent change in the shareholding structure of Bluestar Medical has raised concerns among investors regarding potential interests transfer and the implications of the new indirect controlling shareholder, Langhui Chemical [3][4][5] Group 1: Shareholding Changes - Langhui Chemical has acquired a controlling stake in Bluestar Medical's major shareholder, Zibo Bluestar Investment, through a capital increase, diluting the stake of Bluestar Group from 98% to 47.0013% [5][6] - Despite the change in indirect control, the actual controller, Li Zhenping, remains unchanged, and the company asserts that this does not affect the control or business structure of Bluestar Medical [5][6][9] Group 2: Financial Performance and Transactions - Langhui Chemical, previously a loss-making subsidiary, has transformed into a leading enterprise in the plasticizer and resin sector, with revenues of approximately 12.15 billion, 12.69 billion, and 13.42 billion from 2022 to 2024 [6][11] - Bluestar Medical has reported continuous losses over the past three years, with revenues of approximately 4.9 billion, 4.93 billion, and 6.25 billion, and net losses of approximately 372 million, 568 million, and 446 million during the same period [11] Group 3: Supply Chain and Procurement - Langhui Chemical has been the largest supplier for Bluestar Medical over the past three years, with procurement amounts of approximately 499 million, 496 million, and 577 million, accounting for 15.27%, 12.88%, and 12.52% of total annual procurement [9][10] - Bluestar Medical plans to procure approximately 635 million from Langhui Chemical in 2025, which is significantly higher than from other suppliers, indicating a reliance on this supplier despite the commitment to reduce related transactions [10][11]

序号股票简称PE(TTM)PE(静)市净率总市值(元)24蓝帆医疗-10.45-7.960.5245.22亿行业平均 46.4043.694.51100.23亿行业中值34.8130.782.2645.22亿1硕世生物-1850.69-1850.691.1437.05亿2天益医 疗-1581.08-2708.221.6920.15亿3澳华内镜-525.57263.604.2155.39亿4诺唯赞-508.22-508.222.3391.96亿5康 泰医学-256.3930.082.6249.86亿6奥精医疗-112.48-164.861.4820.87亿7睿昂基因-88.47-72.631.2511.45亿8 热景生物-66.29-66.293.64118.81亿9中红医疗-65.49-52.240.8345.51亿10华大智造-50.86-50.863.82304.72亿 11天智航-41.84-41.844.3751.51亿 4月28日，蓝帆医疗今日收盘4.49元，下跌2.39%，最新市净率0.52，总市值45.22亿元。 来源：金融界 股东方面，截至2025年3月31日，蓝帆医疗股东户数81034户，较 ...

来源：金融界 最新一期业绩显示，2024年三季报，公司实现营业收入46.54亿元，同比29.85%；净利润-219822842.84 元，同比38.19%，销售毛利率17.17%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)24蓝帆医疗-10.52-8.010.5345.52亿行业平均 45.9448.384.71101.41亿行业中值29.6428.792.3545.52亿1天益医疗-2672.56-2672.561.6719.88亿2硕世生 物-1835.15-1835.151.1537.91亿3诺唯赞-549.11-549.112.5299.35亿4博晖创新-335.30-206.443.6951.46亿5康 泰医学-262.5830.812.6851.07亿6华大基因-197.28215.792.04200.47亿7奥精医疗-108.26-108.261.3819.61亿 8睿昂基因-79.59-79.591.2411.51亿9热景生物-60.65-60.653.33108.69亿10华大智造-52.74-52.743.96315.97 亿11中红医疗-48.32-32.870.7743. ...